Technology / Science
A Future Standard of Care
Contact Lens Drug
We have proprietary printing technology and ink that allows for the sustained, continuous release of ophthalmic drugs via contact lenses and it is called the MediPrint™ process.
Our unique process results in a novel way to for treat various eye diseases and conditions with a non-invasive, cost-effective treatment.
We have an extensive global patent portfolio, comprising intellectual property around the world and covering glaucoma, dry eye, myopia, etc.
MediPrint™ lenses are the
convenient, efficient and comfortable way to deliver
ocular medications to the eye non-invasively.
• No daily drops
• Continuous therapy
• Cost neutrality
• More satisfied members and providers
• Higher patient satisfaction
• Greater income potential
Current Treatments’ Shortcomings
While eye drops have been around for over 40 years and remain the standard of care for over 90% of patients, they are plagued by only around a 50% compliance rate, by low bioavailability and by side effects.
This leads millions to continue to suffer, including from disease progression, and even thousands to experience preventable blindness.
There are vast unmet needs for better non-invasive and cost-effective treatment options in numerous multi-billion dollar markets.
Proprietary MediPrint™ Process
Unique contact lens drug delivery platform for effectively treating ocular diseases.
Our unique process results in a novel way to treat various eye diseases and conditions with a non-invasive, cost-effective treatment.
Drug delivery via contact lenses may have many benefits, including improved bioavailability, better patient compliance and reduced side effects.
The innovative MediPrint™ solution also mitigates regulatory risks, works seamlessly with existing high speed manufacturing processes and offers eye care professionals new treatment choices.
The value-added benefits may make these a first line choice for treatments